Activating KRAS mutation is prognostic only among patients who receive preoperative chemotherapy before resection of colorectal liver metastases

Journal of Surgical Oncology

Volumn 114, Issue 3, 2016, Pages 361-367

  Margonis, Georgios Antonios ^a   Kim, Yuhree ^a   Sasaki, Kazunari ^a   Samaha, Mario ^a   Buettner, Stefan ^a   Amini, Neda ^a   Pawlik, Timothy M ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

CRLM; KRAS mutations; preoperative chemotherapy

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL LIVER METASTASIS; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 84983332088     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.24319     Document Type: Article

References (35)

1. Smith JJ, D'Angelica MI: Surgical management of hepatic metastases of colorectal cancer. Hematol Oncol Clin North Am 2015; 29:61–84.
2. Penna C, Nordlinger B: Colorectal metastasis (liver and lung). Surg Clin North Am 2002; 82:1075–1090;x–xi.
3. D'Angelica M, Kornprat P, Gonen M, et al.: Effect on outcome of recurrence patterns after hepatectomy for colorectal metastases. Ann Surg Oncol 2011; 18:1096–1103.
4. Manfredi S, Lepage C, Hatem C, et al.: Epidemiology and management of liver metastases from colorectal cancer. Ann Surg 2006; 244:254–259.
5. Tzeng CW, Aloia TA: Colorectal liver metastases. J Gastrointest Surg 2013; 17:195–201; quiz p. 201–192.
6. Adam R, de Gramont A, Figueras J, et al.: Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus. Cancer Treat Rev 2015; 41:729–741.
7. Vogelstein B, Fearon ER, Hamilton SR, et al.: Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319:525–532.
8. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 1990; 61:759–767.
9. Lipsyc M, Yaeger R: Impact of somatic mutations on patterns of metastasis in colorectal cancer. J Gastrointest Oncol 2015; 6:645–649.
10. Vauthey JN, Kopetz SE: From multidisciplinary to personalized treatment of colorectal liver metastases: 4 reasons to consider RAS. Cancer 2013; 119:4083–4085.
11. Margonis GA, Spolverato G, Kim Y, et al.: Effect of KRAS mutation on long-term outcomes of patients undergoing hepatic resection for colorectal liver metastases. Ann Surg Oncol 2015; 22:4158–4165.
12. Schirripa M, Bergamo F, Cremolini C, et al.: BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer 2015; 112:1921–1928.
13. Kemeny NE, Chou JF, Capanu M, et al.: KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer 2014; 120:3965–3971.
14. Vauthey JN, Zimmitti G, Kopetz SE, et al.: RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 2013; 258:617–626; discussion 619–627.
15. Stremitzer S, Stift J, Gruenberger B, et al.: KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. Br J Surg 2012; 99:1575–1582.
16. Margonis GA, Kim Y, Spolverato G, et al.: Association between specific mutations in KRAS codon 12 and colorectal liver metastasis. JAMA Surg 2015; 150:722–729.
17. Tejpar S, Celik I, Schlichting M, et al.: Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 2012; 30:3570–3577.
18. Soreide K, Sandvik OM, Soreide JA: KRAS mutation in patients undergoing hepatic resection for colorectal liver metastasis: A biomarker of cancer biology or a byproduct of patient selection? Cancer 2014; 120:3862–3865.
19. Wanebo HJ, LeGolvan M, Paty PB, et al.: Meeting the biologic challenge of colorectal metastases. Clin Exp Metastasis 2012; 29:821–839.
20. Siriwardena AK, Mason JM, Mullamitha S, et al.: Management of colorectal cancer presenting with synchronous liver metastases. Nat Rev Clin Oncol 2014; 11:446–459.
21. Choti MA, Thomas M, Wong SL, et al.: Surgical resection preferences and perceptions among medical oncologists treating liver metastases from colorectal cancer. Ann Surg Oncol 2015; 2:375–381.
22. Mayo SC, Pawlik TM: Current management of colorectal hepatic metastasis. Expert Rev Gastroenterol Hepatol 2009; 3:131–144.
23. Nathan H, Bridges JF, Cosgrove DP, et al.: Treating patients with colon cancer liver metastasis: A nationwide analysis of therapeutic decision making. Ann Surg Oncol 2012; 19:3668–3676.
24. Kemeny NE: Treatment of metastatic colon cancer: “the times they are A-changing”. J Clin Oncol 2013; 31:1913–1916.
25. Adam R, Delvart V, Pascal G, et al.: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 2004; 240:644–657; discussion 657–648.
26. Adam R, Avisar E, Ariche A, et al.: Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001; 8:347–353.
27. Nordlinger B, Sorbye H, Glimelius B, et al.: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 2008; 371:1007–1016.
28. Mise Y, Zimmitti G, Shindoh J, et al.: RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. Ann Surg Oncol 2015; 22:834–842.
29. Primrose J, Falk S, Finch-Jones M, et al.: Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: The New EPOC randomised controlled trial. Lancet Oncol 2014; 15:601–611.
30. Sunakawa Y, Stintzing S, Cao S, et al.: Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: Results from TRIBE and FIRE3 trials. Ann Oncol 2015; 26:2450–2456.
31. Andreou A, Kopetz S, Maru DM, et al.: Adjuvant chemotherapy with Folfox for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Ann Surg 2012; 256:642–650.
32. Santini D, Loupakis F, Vincenzi B, et al.: High concordance of KRAS status between primary colorectal tumors and related metastatic sites: Implications for clinical practice. Oncologist 2008; 13:1270–1275.
33. Knijn N, Mekenkamp LJ, Klomp M, et al.: KRAS mutation analysis: A comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 2011; 104:1020–1026.
34. Italiano A, Hostein I, Soubeyran I, et al.: KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: Biological and clinical implications. Ann Surg Oncol 2010; 17:1429–1434.
35. Etienne-Grimaldi MC, Formento JL, Francoual M, et al.: K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res 2008; 14:4830–4835.